Reports
Sale
Neurodegenerative Diseases Drugs Market Size, Share, Trends: By Drug Class: Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others; By Route of Administration: Oral, Parenteral, Transdermal; By Disease Indication: Multiple Sclerosis, Parkinson’s Disease, Others; Regional Analysis; Supplier Landscape; 2024-2032
Neurodegenerative Diseases Drugs Market Size
The neurodegenerative diseases drugs market was valued at USD 44.69 billion in 2023, driven by rising prevalence of neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease across the 8 major markets The market is expected to grow at a CAGR of 7.1% during the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neurodegenerative Diseases Drugs Market Outlook
- In United States, around 6.7 million individuals aged 65 or above are affected from Alzheimer’s disease. This incidence rate is expected to reach 13.8 million by 2060. The rise in neurodegenerative diseases is expected to boost the market for neurodegenerative disease drugs in the forecast period.
- In January 2023, the FDA approved Eisai’s Leqembi for treatment of Alzheimer's disease. Increased FDA approvals to provide better outcomes to patients is amongst major market trends.
- The market is experiencing an emergence of new biotechnology companies, focused on using latest technologies such as artificial intelligence to boost production of drugs.
Neurodegenerative Diseases Drugs Market Overview
Neurodegenerative diseases drugs are the medications aimed at treating neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and spinal muscular atrophy, among others. These types of drugs can be taken orally, intravenously, or through the skin. Neurodegenerative diseases refer to those diseases and conditions that are caused by a loss in performance or structure of neurons, due to neurodegeneration process. As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
The market value is expected to be impacted by increasing drug approvals by affluent regulatory authorities such as United States FDA to bring effective and affordable treatment alternatives for patients. In addition, integration of artificial intelligence algorithms into drug development, intended to improve efficacy and streamline the drug development process is another factor contributing to market growth.
Neurodegenerative Diseases Drugs Market Growth Drivers
Rising Prevalence of Neurodegenerative Diseases
Neurodegenerative disorders encompass several chronic conditions such as Alzheimer's disease and other memory disorders, ataxia, Huntington's disease, Parkinson's disease, multiple sclerosis, and multiple system atrophy, among others. In United States, Parkinson’s disease incidence rate witnessed steep growth, leading to diagnosis of nearly 90,000 people in the region. In addition, around 6.7 million Americans aged 65 or above are affected from Alzheimer’s disease, with the prevalence rate expected to reach 13.8 million by 2060. Hence, there is increased emphasis on managing the rising burden of neurodegenerative disorders, leading to high demand of drugs and therapeutic alternatives.
Surge in Collaborations Between Leading Companies to Meet Rising Neurodegenerative Diseases Drugs Market Demand
In November 2023, Charles River Laboratories and Aitia collaborated to leverage Logica, Charles River’s artificial intelligence (AI)-powered drug solution platform and develop treatment alternatives for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases. As per the terms of agreement, the two companies are expected to combine their expertise in drug research and development, while incorporating modern technologies to create precise and efficient drugs. Such partnerships are expected to shape the market landscape significantly in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neurodegenerative Diseases Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Increasing Drug Approvals from Regulatory Authorities | The growing approvals of newly developed drugs by regulatory authorities, such as the United States’ FDA are key trends in the neurodegenerative disease drugs market. Regulatory approval helps support the wider access of these drugs, enabling more patients to use them. |
| Preference for Personalized Medicine | With a better understanding of human physiology and technical advancements, there has been a rising inclination towards personalized medicine alternatives. Advances in biomarkers and genomics is enabling the creation of customized drugs based on an individual’s generic makeup, boosting the efficacy of treatment. |
| Growth in Fundings and Investments | The market is witnessing a surge in investments and fundings to boost neurodegenerative drug research. Non-profit organizations, governments and private investors are offering grants and investments to upcoming pharmaceutical companies and research institutions, with an aim to introduce new drugs in the market. |
| Focus on Early Diagnosis | As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease. |
Neurodegenerative Diseases Drugs Market Segmentation
Market Breakup by Drug Class
- Immunomodulator
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Transdermal
Market Breakup by Disease Indication
- Multiple Sclerosis
- Parkinson’s Disease
- Alzheimer's Disease
- Spinal Muscular Atrophy (SMA)
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Neurodegenerative Diseases Drugs Market Share
Market Segmentation Based on Indication is Anticipated to Witness Substantial Growth
Based on indication disease, the market breakup includes multiple sclerosis, Parkinson’s disease, Alzheimer's disease, spinal muscular atrophy (SMA) and others.The Alzheimer's disease segment, based on disease indication, holds a significant share in the neurodegenerative disease drugs market, owing to the high prevalence of this disease among the elderly. The increasing geriatric population is leading to an escalation of the cases of Alzheimer’s disease which is in turn boosting the sale of drugs intended towards treating cognitive manifestations related to this disease.
Meanwhile, cases of Parkinson’s disease are also escalating worldwide, supported by growing awareness and faster diagnoses. Over the forecast period, the increase in awareness about these diseases, along with early diagnostic tools and protocols are expected to fuel the neurodegenerative diseases drugs market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Neurodegenerative Diseases Drugs Market Analysis by Region
Based on region, the market report covers United States, EU-4 (Germany, France, Italy and Spain), United Kingdom, Japan and India. The United States is expected to lead the market share in the forecast period, driven by a favorable regulatory landscape, leading to increased number of drug approvals. In addition, the presence of key healthcare and pharmaceutical companies in the region also boosts the market value. For instance, in January 2023, FDA granted approval to Eisai’s Leqembi (lecanemab-irmb) for treatment of Alzheimer's disease under the accelerated approval pathway. The results were based on Phase 3 randomized, controlled clinical trial, that confirmed the drug's clinical benefits.
In EU-4 and United Kingdom is estimated to hold a significant market share in the forecast period, driven by the emergence of new biotechnology companies in the region. There has been an influx of investments and fundings to support upcoming talent that has the potential to incorporate latest techniques into drug development processes. In June 2023, BIOS Health, a healthcare startup raised USD 20 million from various private investors and expects to utilize the amount in precision trials for neurological therapies.
Countries like Japan and India are emerging markets for neurodegenerative diseases, with the growing awareness leading to early diagnosis and treatment. In addition, increased investments from governments to develop medical infrastructure is projected to boost rapid growth in the coming years.
Leading Players in the Neurodegenerative Diseases Drugs Market
The key features of the market report include patent analysis, clinical trial analysis, grant analysis, funding, and investment analysis as well as strategic initiatives such as recent joint ventures, along with partnerships and collaborations by the leading players. The major companies in the market are as follows:
Pfizer, Inc.
It is one of the largest pharmaceutical manufacturers across the world. This company was founded in the year 1849 and is currently headquartered in New York, United States. Pfizer, Inc. produces medications, drugs, and vaccines, aimed towards battling chronic diseases. It is known for the development of remarkable breakthroughs in the field of pharmaceuticals.
Merck KGaA
Founded in the year 1668 and currently headquartered in Darmstadt, Germany, Merck KGaA is a leading science and technology company, and one of the oldest pharmaceutical companies around the world. It delivers progressive treatment solutions, personalised treatments, and healthcare products for oncology, endocrinology, fertility, neurology, immunology, and general medicine. Apart from healthcare, Merck also specialises in electronics and life sciences.
Novartis AG
Based in Basel, Switzerland, it was founded in the year 1997 and currently innovates and sells medicines and drugs to cure various chronic diseases. Novartis AG has been structured into two companies namely, Innovative Medicines and Sandoz. The company is also a prominent player in the field of science and technology.
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals, an American health care company is known for its therapeutics for Parkinson’s disease psychosis and Rett syndrome. The company is committed to address unmet needs in rare diseases and has several drugs in pipeline for various neurodegenerative diseases.
Other players in the market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Neuronity Therapeutics, Inc., Arkuda Therapeutics Inc., NeuroX1 Inc., and Annovis Bio, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Disease Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Neurodegenerative Diseases Drugs Market Report
- What was the neurodegenerative diseases drugs market value in 2023?
- What is the neurodegenerative diseases drugs market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug classes?
- What is the market breakup based on route of administration?
- Who is the market segmentation based on disease indication?
- What are the major factors aiding the neurodegenerative diseases drugs market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- What drug class will dominate the market share?
- Which disease indication is expected to have a high market value in the coming years?
- Who are the key players involved in the neurodegenerative diseases drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Neurodegenerative Diseases Drugs Market Overview: 8 Major Markets
3.1 Neurodegenerative Diseases Drugs Market Historical Value (2017-2023)
3.2 Neurodegenerative Diseases Drugs Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Neurodegenerative Diseases: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Neurodegenerative Diseases Drugs Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Neurodegenerative Diseases Drugs Market Landscape: 8 Major Market*
8.1 Neurodegenerative Diseases Drugs Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Neurodegenerative Diseases Drugs Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
8.2.3 Analysis by Disease Indication
9 Neurodegenerative Diseases Drugs Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Neurodegenerative Diseases Drugs: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Neurodegenerative Diseases Drugs Market Segmentation: 8 Major Markets
12.1 Neurodegenerative Diseases Drugs Market by Drug Class
12.1.1 Market Overview
12.1.2 Immunomodulator
12.1.3 Interferons
12.1.4 Decarboxylase Inhibitors
12.1.5 Dopamine Agonists
12.1.6 Others
12.2 Neurodegenerative Diseases Drugs Market by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.2.4 Transdermal
12.3 Neurodegenerative Diseases Drugs Market by Disease Indication
12.3.1 Market Overview
12.3.2 Multiple Sclerosis
12.3.3 Parkinson’s Disease
12.3.4 Alzheimer's Disease
12.3.5 Spinal Muscular Atrophy (SMA)
12.3.6 Others
12.4 Neurodegenerative Diseases Drugs Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Neurodegenerative Diseases Drugs Market (2017-2032)
13.1 United States Neurodegenerative Diseases Drugs Market Historical Value (2017-2023)
13.2 United States Neurodegenerative Diseases Drugs Market Forecast Value (2024-2032)
13.3 United States Neurodegenerative Diseases Drugs Market (2017-2032) by Drug Class
13.3.1 Market Overview
13.3.2 Immunomodulator
13.3.3 Interferons
13.3.4 Decarboxylase Inhibitors
13.3.5 Dopamine Agonists
13.3.6 Others
13.4 United States Neurodegenerative Diseases Drugs Market (2017-2032) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.4.4 Transdermal
13.5 United States Neurodegenerative Diseases Drugs Market (2017-2032) by Diseases Indication
13.5.1 Multiple Sclerosis
13.5.2 Parkinson’s Disease
13.5.3 Alzheimer's Disease
13.5.4 Spinal Muscular Atrophy (SMA)
13.5.5 Others
14 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2017-2032)
14.1 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2017-2032) by Drug Class
14.3.1 Market Overview
14.3.2 Immunomodulator
14.3.3 Interferons
14.3.4 Decarboxylase Inhibitors
14.3.5 Dopamine Agonists
14.3.6 Others
14.4 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Transdermal
14.5 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2017-2032) by Disease Indication
14.5.1 Multiple Sclerosis
14.5.2 Parkinson’s Disease
14.5.3 Alzheimer's Disease
14.5.4 Spinal Muscular Atrophy (SMA)
14.5.5 Others
15 Japan Neurodegenerative Diseases Drugs Market
15.1 Japan Neurodegenerative Diseases Drugs Market Historical Value (2017-2023)
15.2 Japan Neurodegenerative Diseases Drugs Market Forecast Value (2024-2032)
15.3 Japan Neurodegenerative Diseases Drugs Market (2017-2032) by Drug Class
15.3.1 Market Overview
15.3.2 Immunomodulator
15.3.3 Interferons
15.3.4 Decarboxylase Inhibitors
15.3.5 Dopamine Agonists
15.3.6 Others
15.4 Japan Neurodegenerative Diseases Drugs Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Transdermal
15.5 Japan Neurodegenerative Diseases Drugs Market (2017-2032) by Disease Indication
15.5.1 Multiple Sclerosis
15.5.2 Parkinson’s Disease
15.5.3 Alzheimer's Disease
15.5.4 Spinal Muscular Atrophy (SMA)
15.5.5 Others
16 India Neurodegenerative Diseases Drugs Market
16.1 India Neurodegenerative Diseases Drugs Market (2017-2032) Historical Value (2017-2023)
16.2 India Neurodegenerative Diseases Drugs Market (2017-2032) Forecast Value (2024-2032)
16.3 India Neurodegenerative Diseases Drugs Market (2017-2032) by Drug Class
16.3.1 Market Overview
16.3.2 Immunomodulator
16.3.3 Interferons
16.3.4 Decarboxylase Inhibitors
16.3.5 Dopamine Agonists
16.3.6 Others
16.4 India Neurodegenerative Diseases Drugs Market (2017-2032) by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.4.4 Transdermal
16.5 India Neurodegenerative Diseases Drugs Market (2017-2032) by Disease Indication
16.5.1 Multiple Sclerosis
16.5.2 Parkinson’s Disease
16.5.3 Alzheimer's Disease
16.5.4 Spinal Muscular Atrophy (SMA)
16.5.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Pfizer, Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Merck KGaA
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Novartis AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Acadia Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Teva Pharmaceutical Industries Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 F. Hoffmann-La Roche Ltd
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Neuronity Therapeutics, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Arkuda Therapeutics Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 NeuroX1 Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Annovis Bio, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Neurodegenerative Diseases Drugs Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER